Results show that cadonilimab, a bispecific antibody, combined with chemotherapy is highly effective as a first-line treatment for advanced or recurrent endometrial cancer.
In the study of 41 evaluable patients, 78% experienced significant tumor shrinkage and 97.6% achieved disease control, meaning most patients had either tumor reduction or stable disease. The median progression-free survival was 17.77 months, and the 12-month overall survival rate was 88.1%.
Notably, the treatment worked well even in patients with pMMR tumors, which usually respond poorly to immunotherapy. Side effects were generally manageable, with severe toxicities occurring in fewer than 20% of patients and mainly involving skin reactions, allergies, and immune-related hormone issues.
Overall, the results suggest that cadonilimab combined with chemotherapy may offer a strong new first-line option for advanced endometrial cancer with durable disease control.